These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35873941)

  • 1. Diabetic Retinopathy: An Overview of Treatments.
    Mounirou BAM; Adam ND; Yakoura AKH; Aminou MSM; Liu YT; Tan LY
    Indian J Endocrinol Metab; 2022; 26(2):111-118. PubMed ID: 35873941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of Diabetic Retinopathy at Eye Clinic Svjetlost Sarajevo: Two Years Retrospective Single Center Study.
    Pidro A; Ahmedbegovic-Pjano M; Grisevic S; Sofic-Drino V; Gabric K; Biscevic A
    Mater Sociomed; 2019 Dec; 31(4):290-293. PubMed ID: 32082096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.
    Tomita Y; Lee D; Tsubota K; Negishi K; Kurihara T
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.
    Arrigo A; Aragona E; Bandello F
    Ann Med; 2022 Dec; 54(1):1089-1111. PubMed ID: 35451900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?
    Arabi A; Tadayoni R; Ahmadieh H; Shahraki T; Nikkhah H
    J Ophthalmic Vis Res; 2022; 17(1):108-117. PubMed ID: 35194501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of diabetic retinopathy: a systematic review.
    Mohamed Q; Gillies MC; Wong TY
    JAMA; 2007 Aug; 298(8):902-16. PubMed ID: 17712074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing disutility associated with diabetic retinopathy, diabetic macular oedema and associated visual impairment using the Vision and Quality of Life Index.
    Fenwick EK; Xie J; Pesudovs K; Ratcliffe J; Chiang PP; Finger RP; Lamoureux EL
    Clin Exp Optom; 2012 May; 95(3):362-70. PubMed ID: 22537275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diabetic retinopathy].
    Barth T; Helbig H
    Klin Monbl Augenheilkd; 2021 Oct; 238(10):1143-1159. PubMed ID: 34380155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
    Simó R; Carrasco E; García-Ramírez M; Hernández C
    Curr Diabetes Rev; 2006 Feb; 2(1):71-98. PubMed ID: 18220619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction Between the Distribution of Diabetic Retinopathy Lesions and the Association of Optical Coherence Tomography Angiography Scans With Diabetic Retinopathy Severity.
    Ashraf M; Sampani K; Rageh A; Silva PS; Aiello LP; Sun JK
    JAMA Ophthalmol; 2020 Dec; 138(12):1291-1297. PubMed ID: 33119083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy.
    Bahr TA; Bakri SJ
    Life (Basel); 2023 Apr; 13(5):. PubMed ID: 37240743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of choroidal thickness with diabetic retinopathy at different stages].
    Wang S; Lin S; Zheng Y; Di F; Cao X; Liu C; Yang J
    Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(32):2584-8. PubMed ID: 26711604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor therapy for diabetic macular edema.
    Boyer DS; Hopkins JJ; Sorof J; Ehrlich JS
    Ther Adv Endocrinol Metab; 2013 Dec; 4(6):151-69. PubMed ID: 24324855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
    Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
    JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients.
    Kim JT; Lee DH; Joe SG; Kim JG; Yoon YH
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3378-84. PubMed ID: 23611988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
    Chatziralli I; Loewenstein A
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452097
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.